Centene Earnings Beat Streak Masks Sequential EPS Drop
Centene has beaten analyst estimates four quarters running, but absolute EPS fell 83 percent from $3.37 to $0.58 as consensus forecasts fell faster than actual results. While the company maintains a s
Centene Earnings Beat Streak Masks Sequential EPS Drop
NEW YORK, November 10 —
Centene Corporation (CNC) has beaten analyst earnings estimates four quarters running, most recently by 493.8%, yet absolute quarterly EPS has fallen from $3.37 to $0.58 over that same span. The gap forces a pointed question: has the managed care giant found a floor, or have analysts simply lowered the bar faster than results decline?
- General Counsel Christopher Koster sold $6.89 million in two open-market trades in August 2026; no insiders bought.
The Lowered-Bar Problem
Centene runs the managed care model at its most margin-compressed: the Medicaid segment, covering everything from CHIP enrollment to aged-and-disabled programs, is the core of its $180 billion revenue base. At 11.3% gross margin, there is little cushion when medical costs run hot. Centene beat a floor analysts had all but placed at ground level; the 493.8% headline says more about forecaster confidence than about business trajectory.
The Balance Sheet Gives the Bull Case Its Legs
Strip away the quarterly noise and the financial infrastructure stays formidable: $23.59 billion in cash against $15.54 billion in debt, $3.08 billion in trailing free cash flow, and a 12.3x forward P/E at $68.44, with the analyst consensus target at $75.39. For a managed care operator covering Medicaid enrollees across commercial marketplace and Medicare lines, the cash cushion absorbs the medical-cost spikes that periodically compress a razor-thin margin. The fuller picture of Centene Corporation's latest numbers shows a business that remains cashflow-positive even as the quarterly earnings trajectory softens. If the sequential decline has bottomed, the multiple looks like reasonable entry.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| CNC | $33.9B | 12.3x | +93.8% |
| HUM | $52.4B | 25.1x | +73.8% |
| MOH | $10.6B | 21.4x | +41.7% |
| CI | $79.5B | 9.0x | +10.3% |
| HCA | $105.8B | 16.2x | +9.2% |
| EW | $59.5B | 30.4x | +23.0% |
The Insider Exit Complicates the Recovery Thesis
General Counsel Christopher Koster executed two open-market sales in August 2026, clearing $6.89 million at prices between $65.36 and $66.90, both below the current $68.44 stock price. No insider bought. The legal officer's discretionary exits, timed before a quarter in which analyst estimates collapsed to near-zero, raise a credibility question the balance sheet cannot settle on its own. The 12.3x forward P/E implies the market is pricing in recovery; a fourth consecutive sequential EPS decline in Q4 2026 would invalidate that thesis directly. See the full DCF model and price target →
Current fundamentals, valuation and filing history for Centene Corporation (CNC) are tracked on its Basis Report page.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Did Centene beat Q3 2026 earnings estimates?
Yes, Centene beat Q3 2026 estimates significantly, reporting EPS of $0.58 against a $0.097 consensus for a 493.8% beat. However, analyst estimates fell 91 percent between Q2 and Q3, from $1.079 to $0.097, while actual EPS declined from $2.51 to $0.58, creating a disconnect between headline performance and underlying earnings deterioration.
Why is Centene's absolute EPS declining despite consecutive beats?
Centene's core Medicaid business operates at only 11.3 percent gross margin, leaving minimal cushion when medical costs spike. Over four quarters, absolute EPS has fallen from $3.37 to $0.58, a decline of 83 percent. The company beats estimates not because operations are improving, but because analysts have lowered their estimates faster than results are falling.
What is Centene's financial position?
Centene maintains $23.59 billion in cash against $15.54 billion in debt and generated $3.08 billion in trailing free cash flow. The company trades at 12.3x forward P/E, with an analyst consensus price target of $75.39. This strong balance sheet provides cushion against the medical-cost spikes that periodically compress Medicaid margins.
Why did Centene's General Counsel sell stock?
General Counsel Christopher Koster sold $6.89 million in stock in August 2026 at prices between $65.36 and $66.90, both below the current $68.44 stock price. No insiders bought. The timing of these discretionary sales before a quarter in which analyst estimates collapsed by 91 percent raises questions about management confidence in the recovery thesis.
What would invalidate Centene's recovery thesis?
A fourth consecutive sequential EPS decline in Q4 2026 would directly invalidate the market's implied recovery pricing at 12.3x forward P/E. The balance sheet strength suggests the current decline may be temporary if medical costs stabilize, but recent insider selling complicates confidence in that outcome.
Centene Corporation has beaten analyst earnings estimates in each of the last four quarters, including a 493.8% upside surprise in Q3 2026 — yet its absolute quarterly EPS has fallen from $3.37 to $0.58 over that same span. Investors must now decide whether the managed care giant is nearing an earnings floor or whether Wall Street is simply cutting estimates faster than results decline.